HUMAN IMMUNOGLOBULIN (PH4) FOR INTRAVENOUS INJECTION MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Human Immunoglobulin (pH4) for Intravenous Injection Market is estimated to be valued at USD 88.56 Bn in 2026 and is expected to reach USD 208.34 Bn in 2033, exhibiting a compound annual growth rate (CAGR) of 13.0% from 2026 to 2033. For instance, according to the data provided by National Health Service- the publicly funded healthcare system in England, the immunoglobulin used to treat Kawasaki disease is called gamma globulin. After the administration of IVIG, symptoms of fever, flu, or rash improve within 36 hours.

Figure 1. Global Human Immunoglobulin (pH4) for Intravenous Injection Market Share (%), by Disease Indication, 2026

Global Human Immunoglobulin (pH4) for Intravenous Injection Market – Drivers

Increasing incidence of disease outbreaks

The increasing incidence of disease outbreaks is escalating demand for advanced diagnostic measures, which is expected to boost the growth of the global human immunoglobulin (pH4) for intravenous injection market.

Increasing approval of intravenous human immunoglobulin products

Approvals of intravenous human immunoglobulin products by regulatory authorities are expected to drive the growth of the human immunoglobulin (pH4) for the intravenous injection market during the forecast period. For instance, on May 4, 2023, The U.S.

Figure 2. Global Human Immunoglobulin (pH4) for Intravenous Injection Market Share (%), by Region, 2026

Global Human Immunoglobulin (pH4) for Intravenous Injection Market - Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global human immunoglobulin ph4 for intravenous injection market over the forecast period.

Since the virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

Global Human Immunoglobulin Ph4 For Intravenous Injection Market Segmentation:

The global human immunoglobulin ph4 for intravenous injection market report is segmented into product type, interface, end user, and region.

By Product Type, the market is segmented into IgG, IgA, and IgM. Out of which, the igG segment is expected to hold a dominant position in the global human immunoglobulin ph4 for intravenous injection market during the forecast period and this is attributed to their higher affinity and ability to neutralize toxins, viruses, and bacteria.

By Disease Indication,

By Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

By Region, the market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Global Human Immunoglobulin Ph4 For Intravenous Injection Market Cross Sectional Analysis:

Among product type, IgG segment is expected to dominate in North America region during the forecast period owing to the reliance of patients on IgG Therapy for treating various illnesses. For instance, according to data published in December 2022, in PubMed- a free search engine for biological databases and medical reports, over 41% of adults with generalized myasthenia gravis (gMG) in the U.S. who had been prescribed a  treatment of intravenous immunoglobulin (IVIG), became frequent users with an average of 6 doses administered each year.

Global Human Immunoglobulin Ph4 For Intravenous Injection Market : Key Developments

 In July 2022, Takeda Pharmaceutical Company Limited- a Japan-based multinational pharmaceutical company, announced positive results from phase 3 clinical trial evaluating HYQVIA (Immune Globulin Infusion 10% IVIG with Recombinant Human Hyaluronidase) for maintenance treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).

According to an article published in October 2022, in PubMed- a medical database for doctors and healthcare professionals, a 16-week trial conducted in dermatomyocitis patients in 2022 showed that IVIG enabled better improvement in disease condition in comparison to placebo.

In May 2020, The Food and Drug Administration (FDA) approved Octapharma Brasil Ltd

Global Human Immunoglobulin Ph4 For Intravenous Injection Market: Key Trends

Kamada will carry out product development, manufacturing, and clinical development, in collaboration with Kedrion S.p.A.

In November  2020,  the U.S. Bamlanivimab is a monoclonal antibody that is specifically directed against the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells.

Global Human Immunoglobulin Ph4 For Intravenous Injection Market: Restraints

The inefficiency of immunoglobulins to treat

The ineffectiveness of immunoglobin therapies can restrain the growth of the global human immunoglobulin ph4 for intravenous injection market.

Test and trial in non-hospitalized patients and more investigations about the drug regimen can serve as an effective counterbalance to determine the actual efficacy of immunoglobins.

Lack of approval from WHO

Global Human Immunoglobulin Ph4 For Intravenous Injection Market - Key Players

Major players operating in the global human immunoglobulin ph4 for intravenous injection market include Takeda Pharmaceutical Company Limited, Baxter, CSL, Bayer AG, Grifols, S.A, Octapharma Brasil Ltda, Shanghai RAAS Blood Products Co Ltd, Hualan Biological Engineering, Inc, Top Bio Group Co, Ltd (A subsidiary of China Biologic Products Holdings, Inc), Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., China Resources Boya Bio-pharmaceutical Group Co Ltd, ADMA Biologics, Inc, Sinopharm Group Co. Ltd.

*Definition: Intravenous immunoglobulin (IVIG) contains the pooled immunoglobulin G (IgG) immunoglobulins from the plasma of approximately a thousand or more blood donors. IVIGs are sterile, purified IgG products manufactured from pooled human plasma and typically contain more than 95% unmodified IgG, which has intact Fc-dependent effector functions and only trace amounts of immunoglobulin A (IgA) or immunoglobulin M (IgM).